JAK inhibitors, an 'oral drug' that initially gained attention in the field of autoimmune diseases, are now considered one of the treatment options.

The first approved ‘Xeljanz (tofacitinib)’ has accumulated a ten-year prescription record. The fifth JAK inhibitor, ‘Jyseleca (filgotinib),’ is now available on the reimbursement listing.

With their convenient oral administration, JAK inhibitors have emerged as favorable treatment options, providing an alternative to injectable anti-TNF inhibitors.

In the medical field, JAK inhibitors are now considered a treatment option for patients with conditions such as rheumatoid arthritis and ankylosing spondylitis.
<